NASDAQ:CRIS Curis (CRIS) News Today $6.59 -1.01 (-13.29%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$6.00▼$7.4350-Day Range$7.60▼$131.8052-Week Range$6.00▼$20.00Volume202,048 shsAverage Volume15,414 shsMarket Capitalization$38.78 millionP/E RatioN/ADividend YieldN/APrice Target$90.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCuris (NASDAQ:CRIS) Hits New 52-Week Low at $6.00americanbankingnews.com - October 1 at 1:44 AMBuy Rating for Curis (CRIS) Amidst Reverse Stock Split and Revised Launch Estimates for Key Product, Emavusertibmarkets.businessinsider.com - September 29 at 3:42 PMHC Wainwright Weighs in on Curis, Inc.'s FY2023 Earnings (NASDAQ:CRIS)americanbankingnews.com - September 28 at 1:22 AMCuris Reaches New 52-Week High (CRIS)thestreet.com - September 26 at 9:08 PMCuris (NASDAQ:CRIS) Given "Buy" Rating at HC Wainwrightamericanbankingnews.com - September 26 at 4:12 AMCuris (NASDAQ:CRIS) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - September 26 at 3:32 AMHC Wainwright & Co. Reiterates Curis (CRIS) Buy Recommendationnasdaq.com - September 25 at 4:38 PMAnalyst Ratings for Curismarkets.businessinsider.com - September 25 at 11:38 AMPromising Developments in Curis’s AML and MDS Treatment Research Bolster Buy Rating: A Detailed Look at Emavusertib’s Potentialmarkets.businessinsider.com - September 25 at 6:38 AMCuris Announces Date for the 2nd Symposium on IRAK4 in Cancerfinance.yahoo.com - September 12 at 6:48 PMNFL fans roasted Cris Collinsworth for trying to argue that Patrick Mahomes is underratedftw.usatoday.com - September 10 at 6:05 PMExpert Ratings for Curismarkets.businessinsider.com - September 7 at 3:30 PMOne of America's Fastest Growing Healthcare Groups, Curis Functional Health, Partners With Adonis to Centralize Revenue Operationstechnews.tmcnet.com - August 17 at 5:58 PMCuris, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 5 at 8:39 AMCuris: Q2 Earnings Snapshotwashingtonpost.com - August 3 at 7:32 PMCuris (CRIS) Reports Q2 Loss, Misses Revenue Estimatesmsn.com - August 3 at 7:32 PMCuris (CRIS) Price Target Decreased by 11.11% to 6.12msn.com - August 3 at 7:32 PMCuris Provides Second Quarter 2023 Business Updatefinance.yahoo.com - August 3 at 7:32 PMCuris to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023finance.yahoo.com - July 28 at 10:36 AMCantor Fitzgerald Reiterates Curis (CRIS) Overweight Recommendationmsn.com - July 11 at 3:27 PMAnalyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Studymarkets.businessinsider.com - July 7 at 4:44 PMHC Wainwright & Co. Maintains Curis (CRIS) Buy Recommendationmsn.com - July 7 at 11:43 AMCuris launches ~$15.1M registered direct offeringseekingalpha.com - July 6 at 12:28 PMCuris: FDA Removes Partial Clinical Hold On TakeAim Leukemia Studymarkets.businessinsider.com - July 6 at 12:28 PMCuris Announces $15.1 Million Registered Direct Offeringfinance.yahoo.com - July 6 at 12:28 PMCuris says FDA lifted partial clinical hold on leukemia trialmsn.com - July 6 at 12:28 PMWhy Curis (CRIS) Shares Are Nosediving Thursdaymsn.com - July 6 at 12:28 PMFDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BIDprnewswire.com - July 6 at 8:11 AMInvestors in Curis (NASDAQ:CRIS) have unfortunately lost 50% over the last five yearsfinance.yahoo.com - June 30 at 8:08 AMIs Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount?finance.yahoo.com - June 6 at 8:57 AMIs Curis (NASDAQ:CRIS) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - May 15 at 3:13 PMCuris (CRIS) Gets a Buy from JonesTradingmarkets.businessinsider.com - May 9 at 12:39 PMCuris Provides First Quarter 2023 Business Updatefinance.yahoo.com - May 4 at 7:26 PMCuris to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023finance.yahoo.com - April 27 at 8:15 PMCuris, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growthfinance.yahoo.com - April 17 at 8:43 AMCuris to grant stock options for 135.45K shares to new hireseekingalpha.com - April 8 at 1:08 PMCuris, Inc. Common Stock (CRIS)nasdaq.com - April 7 at 5:37 AMCuris to Present at Upcoming Healthcare Conferences in Aprilfinance.yahoo.com - April 3 at 10:27 AMCuris's Return On Capital Employed Overviewbenzinga.com - March 17 at 7:46 AMCuris, Inc. (NASDAQ:CRIS) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 14 at 5:10 PMQ4 2022 Curis Inc Earnings Callfinance.yahoo.com - March 13 at 11:43 PMCuris (CRIS) Reports Q4 Loss, Misses Revenue Estimatesfinance.yahoo.com - March 13 at 6:42 PMCuris Provides Fourth Quarter 2022 Business Updatefinance.yahoo.com - March 13 at 8:25 AMWhat Wall Street expects from Curis's earningsmarkets.businessinsider.com - March 13 at 3:24 AMCuris Reschedules Fourth Quarter 2022 Business Update and Conference Callfinance.yahoo.com - March 9 at 12:12 AMCuris to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023finance.yahoo.com - March 2 at 7:47 PMInvestors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the last five yearsfinance.yahoo.com - January 20 at 1:17 PMCuris Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDSfinance.yahoo.com - December 12 at 6:06 PMmarketbeat.com - December 12 at 10:05 AMCuris to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemiaprnewswire.com - December 5 at 11:28 PM Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Media Mentions By Week CRIS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRIS News Sentiment▼-0.200.69▲Average Medical News Sentiment CRIS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRIS Articles This Week▼161▲CRIS Articles Average Week Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SAB Biotherapeutics News Today Acorda Therapeutics News Today Sangamo Therapeutics News Today Dyadic International News Today Outlook Therapeutics News Today OKYO Pharma News Today Precision BioSciences News Today Instil Bio News Today Solid Biosciences News Today Brainstorm Cell Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:CRIS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.